Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tricaine, most commonly used as its salt form tricaine methanesulfonate, is a small molecule anesthetic primarily used for anesthesia, sedation, or euthanasia of fish and other aquatic cold-blooded animals. It is the only anesthetic licensed in the United States for use in fin fish intended for human consumption. Tricaine acts by blocking sodium ion channels in nerve cells, thereby inhibiting action potentials and silencing neural activity between the brain and extremities. This mechanism results in effective immobilization and loss of sensation during handling or procedures such as spawning, surgery, transport, or research[1][2][4]. The drug is highly water-soluble but can acidify water; buffering may be required to maintain safe pH levels[4]. Major brand names include Finquel (manufactured by MSD Animal Health) and Syncaine (manufactured by Syndel)[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tricaine methanesulfonate.